Peppermint Venture Partners
VC Fund
Berlin, Germany
Peppermint Venture Partners is a VC fund in Berlin focused on Health Care and Medical. PVP is a private venture capital firm based in Berlin, investing in early-stage healthcare companies across Europe with a focus on medical device, digital health, and platform technology companies. Peppermint VenturePartners was established in 2008 by Ingeborg Neumann, Dr. Joachim Rautter and Dr. Klaus Stöckemann.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 29%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Peppermint Venture Partners invests in
Stages Peppermint Venture Partners invests in
Countries Peppermint Venture Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $1.8M–$4.9M
- Series B
- $3M–$11M
- Series C
- $7.6M–$7.8M
Investment Focus
Industry
- Health Care 5 (36%)
- Medical 4 (29%)
- Biotechnology 4 (29%)
- Medical Device 3 (21%)
- Hospital 1 (7%)
Stage
- Series B 4 (29%)
- Series C 3 (21%)
- Series A 2 (14%)
- Series D 1 (7%)
- Venture - Series Unknown 1 (7%)
Country
- Germany 6 (43%)
- Belgium 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Joachim Rautter
Co-Founder and Managing Director
|
Co-Founder and Managing Director | Total investments: 5 | Find email | |
Klaus Stoeckemann
Managing Director & Co-Founder
|
Managing Director & Co-Founder | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | $10.8M / Series B / Apr 02, 2024 | ||
| Labforward supports laboratory teams on their quest for groundbreaking discoveries and delivering innovative high-quality products. With digital tools for laboratories, it increases productivity and improves efficiency in laboratories. The company's products include the user-friendly electronic laboratory notebook (ELN) Labfolder and theInternet-of-Things (IoT) platform Laboperator. The digital connectivity of laboratories and innovative data management is a focus topic in industry and research. In a fragmented landscape of high-tech equipment and specialized software, Labforward links data silos and helps to eliminate costly and error-prone data transfers. Based on this horizontal connectivity, the software Laboperator enables the remote control and monitoring of laboratory equipment, the integration of LIMS systems, databases and special software as well as the automation of workflows. The Labfolder data platform aggregates both automatically recorded and manually added data and enables the review, sharing, retrieval and validation of data by means of a collaborative ELN. Whether life sciences, chemical synthesis, analytics, quality control or research and development: no matter how specific the field or task of a laboratory may be, the way it works and the requirements for data management have a common core. Labforward focuses on this core. | $6.1M / Series B / Jan 08, 2021 | ||
| CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | $7.7M / Series B / Jun 27, 2019 | ||
| Implandata Ophthalmic Products is an early stage, privately-held, venture capital funded medical device company based in Hannover, Germany. Implandata Ophthalmic Products is a medical device company offering a new technology for the treatment and management of glaucoma patients. It identifies an underserved area in care of glaucoma patients,creating disruptive solutions for better and more efficient glaucoma therapy, to the benefit of glaucoma patients, families, and care givers by integrating innovative medical technology with information technology.IOP has developed a novel technology for 24 hour measurement of intraocular pressure, by which monitoring and therapy of glaucoma patients will be improved. This solution will allow a more efficient treatment and management of glaucoma patients.Implandata Ophthalmic Products was founded on 2010. | Series C / May 14, 2018 | ||
| Miracor Medical operates as a medical device company. It develops and commercializes a pressure-controlled intermittent coronary sinus occlusion (PiCSO) impulse system for cardiac surgeons to facilitate the PiCSO treatment for myocardial infarction/heart attack patients undergoing coronary artery bypass grafting surgery. Miracor Medicaloffers a therapy for improving micro-vascular perfusion functions through the coronary sinus. Werner Mohl founded it in 2008, with its headquarters in Awans in Belgium. | $30.2M / Series D / Jan 04, 2018 | ||
| Miracor Medical operates as a medical device company. It develops and commercializes a pressure-controlled intermittent coronary sinus occlusion (PiCSO) impulse system for cardiac surgeons to facilitate the PiCSO treatment for myocardial infarction/heart attack patients undergoing coronary artery bypass grafting surgery. Miracor Medicaloffers a therapy for improving micro-vascular perfusion functions through the coronary sinus. Werner Mohl founded it in 2008, with its headquarters in Awans in Belgium. | $7.6M / Series C / Oct 25, 2016 | ||
| CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries. | $5.8M / Series B / Jul 07, 2016 | ||
| Emperra E-Health Technologies develops GSM and web based Tele-medical products for tracking, monitoring, and transmission of diagnostic and therapeutic data of diabetic patients such as insulin doses, blood sugar levels and carbohydrates. The company was founded in 2008 and is based in Potsdam, Germany. | $3M / Series B / Jan 04, 2016 | ||
| CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system.CAP-Go enables the production of proteins “beyond antibodies”. Complex, glycosylated proteins represent a significant portion of the human proteome and are notoriously difficult to express in conventional cell lines such asCHO. The CAP-Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand tailor-made glycosylation patterns. | $4.9M / Venture - Series Unknown / Jul 30, 2015 | ||
| Humedics, based in Berlin, focuses on rapid and precise liver function measurement using LiMAx, its innovative breath analysis technology. This easy-to-use bedside test provides doctors with accurate information to support decision making in tailoring the medical treatment to the individual level of each patient and to improve patient outcomes.LiMAx has already been used on thousands of patients and the company is currently expanding its operation globally. | $7.8M / Series C / Nov 10, 2014 | ||
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Peppermint Venture Partners invest in?
Peppermint Venture Partners invests primarily in Health Care, Medical and Biotechnology startups, most often at Series B and Series C stage. Most of the 14 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Peppermint Venture Partners's check size?
Peppermint Venture Partners typically joins rounds of $1.8M–$4.9M at Series A, $3M–$11M at Series B and $7.6M–$7.8M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Peppermint Venture Partners participates in.
How do I contact Peppermint Venture Partners?
Public channels for Peppermint Venture Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Peppermint Venture Partners?
The team at Peppermint Venture Partners includes Joachim Rautter (Co-Founder and Managing Director) and Klaus Stoeckemann (Managing Director & Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
